CBOE : ADME

Aptus Drawdown Managed Equity ETF

$55.1708 USD

-$0.45 (-0.81%)

Volume
7.9K
Average Volume
14.3K
Market Capitalization
$287.86M
P/E Ratio
Dividend Yield
%
Price Target
Year High
$56.67
Year Low
$48.09
Day High
Day Low
Payout Ratio
Current Ratio
Source Headline
Onco-Innovations Initiates ADME Studies Supporting Development of ONC010

Vancouver, Canada – July 16, 2026 – TheNewswire - Onco-Innovations Limited ( CBOE CA: ONCO ) (OTCQB: ONNVF ) (Frankfurt: W1H , WKN: A3EKSZ ) (" Onco " or the " Company ”) announces, further to its news release dated May 8, 2026, the initiation of key absorption, distribution, metabolism and excretion ("ADME") studies for ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. The studies are designed to characterize ONC010's pharmacokinetic and metabolic profile and support the continued IND-enabling development of the program.

thenewswire.com - 2026-07-16 18:00:00

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific  and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.

prnewswire.com - 2026-05-26 12:33:00

Get ADME Insider Trade Alerts

ADME Price Target Summary

Last Month

0 analysts

Last Quarter

0 analysts

Last Year

0 analysts

All Time

0 analysts

ADME Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade